ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.32 · Revenue $12.30M · 2 analysts
Est. EPS $-0.29 · Revenue $13.65M · 2 analysts
Est. EPS $-1.30 · Revenue $49.00M · 2 analysts
Est. EPS $-0.30 · Revenue $13.50M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $37.0M | +17.8% | -10.3% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-25.5M | -35.0% | -18.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +61.4% | +0.8% | +2.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -65.4% | -3.9% | -34.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -69.1% | -14.6% | -32.3% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-24.4M | -165.0% | +16.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -66.1% | -125.0% | +6.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 207.8% | +1378.8% | +75.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 5.91x | +83.3% | -18.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $97.7M | +149.4% | -7.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.90 vs -0.83 | -8.4% | -0.38 vs -0.29 | -32.6% |
| Revenue Surprise | $37.0M vs $36.6M | +1.0% | $10.9M vs $12.7M | -14.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | BURNETT JOSEPH | director, officer: CEO and President | Common Stock | A | 12,517 | $3.47 |
| Sep 2, 2026 | BURNETT JOSEPH | director, officer: CEO and President | Stock Options (right to buy) | D | 12,517 | $3.47 |
| Jul 1, 2026 | FLETCHER R JOHN | director | Common Stock | A | 662 | $17.84 |
| Jul 1, 2026 | Richards Timothy T. | director | Common Stock | A | 222 | $17.84 |
| Jun 30, 2026 | STIGALL L. JEREMY | officer: Chief Business Officer | Common Stock | A | 1,781 | $11.93 |
Operator: Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, the company's plans, prospects and strategies and its beliefs, estimates or projections regarding future revenue and results of operations. You are cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they are made. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for the new information or future events except as required by law. For more information about the company's risks and uncertainties, please refer to the company's filings with the SEC, including the company's recent filings on Form 8-K, Form 10-K and Form 10-Q. All the company's filings may be obtained from the SEC or the company's website at www.clearpointneuro.com. And now I'll turn the call over to Joe Burnett, Chief Executive Officer. Thank you. You may begin. Joseph Burnett: Thank you. And as always, thank you to all the investors, analysts, and biopharma partners listening to today's call. We remain both committed to and focused on developing a complete neuro ecosystem capable of delivering various minimally invasive treatments, including cell and gene therapies to the brain. We believe that this approach will finally unlock hope for the patients and their families who are battling these frightening neurologic disorders and who today have very few options to choose from. This is one of the largest unmet needs in all of medicine and we at ClearPoint believe that we can play an important, if not essential, role in this exciting future. The second quarter of 2026 in itself has been an exciting one and possibly one of the most important series of events in our history. While our long-term vision remains unchanged, anchored by our 4-pillar growth strategy, there has been substantial progress leading us to up-prioritize certain parts of the strategy and to take advantage of this new information from the last few months. So today, instead of looking to the horizon and reconfirming our long-term strategy, I will focus on these 3 most important and elevated priorities that are right in front of us. These 3 activities will represent the largest time and financial investment for the second half of this year. First, we have all seen regulatory updates from pharma partners demonstrating an accelerated pathway to Phase 3 trial enrollment and even commercial approval. This revised potential schedule is much faster than what we believed just 6 months ago and once again has highlighted the need to pursue commercial readiness activities in support of our partners' global launch plans. Second, as of July, we have now taken possession of the 30,000-square-foot CAL preclinical facility in Torrey Pines, California, which includes our analytical lab space. This milestone has enabled us …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Joseph Michael Burnett | President, Chief Executive Officer & Director | USD 1,014,948 | Male | 1977 | Active |
Danilo D'Alessandro | Chief Financial Officer | USD 554,360 | Male | 1985 | Active |
Jeremy Stigall | Chief Business Officer | USD 522,809 | Male | 1984 | Active |
Robert C. Korn | Senior Vice President of Sales & Business Development | USD 305,123 | Male | 1965 | Active |
Paul S. Larson FAANS | Chief Medical Officer | — | — | — | Active |
Megan Faulkenberry | Senior Vice President of Quality | — | Female | — | Active |
Ellisa Cholapranee | General Counsel & Secretary | — | Female | — | Active |
Mary McNamara-Cullinane | Senior Vice President of Regulatory Affairs | — | Female | — | Active |
Mazin Sabra | Chief Operating Officer | — | Male | 1980 | Active |
ClearPoint Neuro (NASDAQ: CLPT) reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery. Total revenue for the three months ended June 30 was $10.9 million, up 18% from $9.2 million in the prior-year period, CFO Danilo D'Alessandro said.
ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.
ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript
The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.
